Tate & Lyle plc (TATE) is a leading packaged foods business based in the UK. It opened the day at 662.8p after a previous close of 664.2p. During the day the price has varied from a low of 657.6p to a high of 665.2p. The latest price was 663p (25 minute delay). Tate-and-Lyle is listed on the London Stock Exchange (LSE) and employs 4,218 staff. All prices are listed in pence sterling.
Since the stock market crash in March caused by coronavirus, Tate-and-Lyle's share price has had significant negative movement.
Its last market close was 646p, which is 18.06% down on its pre-crash value of 788.4p and 30.81% up on the lowest point reached during the March crash when the shares fell as low as 493.83p.
If you had bought £1,000 worth of Tate-and-Lyle shares at the start of February 2020, those shares would have been worth £670.97 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £817.51.
|52-week range||473.1921p - 772.316p|
|50-day moving average||659.0883p|
|200-day moving average||663.4395p|
|Wall St. target price||724.44p|
|Dividend yield||0.3p (4.37%)|
|Earnings per share (TTM)||52.7p|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|3 months (2020-10-16)||2.63%|
|6 months (2020-07-17)||2.44%|
Valuing Tate-and-Lyle stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Tate-and-Lyle's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Tate-and-Lyle's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, Tate-and-Lyle shares trade at around 13x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Tate-and-Lyle's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 34.73. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Tate-and-Lyle's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Tate-and-Lyle's EBITDA (earnings before interest, taxes, depreciation and amortisation) is £493 million.
The EBITDA is a measure of a Tate-and-Lyle's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||£2.8 billion|
|Operating margin TTM||11.56%|
|Gross profit TTM||£1.3 billion|
|Return on assets TTM||6.98%|
|Return on equity TTM||17.6%|
|Market capitalisation||£3.2 billion|
TTM: trailing 12 months
Dividend payout ratio: 5692.31% of net profits
Recently Tate-and-Lyle has paid out, on average, around 5692.31% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.37% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Tate-and-Lyle shareholders could enjoy a 4.37% return on their shares, in the form of dividend payments. In Tate-and-Lyle's case, that would currently equate to about 0.3p per share.
Tate-and-Lyle's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 19 November 2020 (the "ex-dividend date").
Over the last 12 months, Tate-and-Lyle's shares have ranged in value from as little as 473.1921p up to 772.316p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Tate-and-Lyle's is 0.4429. This would suggest that Tate-and-Lyle's shares are less volatile than average (for this exchange).
Tate & Lyle PLC, together with its subsidiaries, provides ingredients and solutions to the food, beverage, and other industries in the United States, the United Kingdom, other European countries, and internationally. It operates through three segments: Food & Beverage Solutions, Sucralose, and Primary Products. The company offers texturants; nutritive sweeteners, such as high fructose corn syrup and dextrose; health and wellness ingredients; and stabilizers. It also provides industrial starches for paper, packaging, and industrial adhesives; acidulants, such as citric acid; and commodities comprising corn gluten feed and meal for animal nutrition, as well as corn oil and ethanol. In addition, the company is involved in the treasury and insurance businesses; and provision of research and development services. Tate & Lyle PLC was incorporated in 1903 and is headquartered in London, the United Kingdom.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Find out the cheapest way to buy shares on Asia’s largest stock exchange.
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
Ever wondered how to buy shares in Van Elle Holdings? We explain how and compare a range of providers that can give you access to many brands, including Van Elle Holdings.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.